-
公开(公告)号:US06835741B2
公开(公告)日:2004-12-28
申请号:US10673100
申请日:2003-09-26
IPC分类号: C07D23332
CPC分类号: C07D401/12 , C07D261/16 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
-
公开(公告)号:US5846990A
公开(公告)日:1998-12-08
申请号:US799616
申请日:1997-02-13
IPC分类号: C07D261/16 , A61K31/42 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61P9/02 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/08 , A61P13/12 , A61P25/06 , A61P43/00 , C07D231/42 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D498/04 , C07D521/00 , A61K31/465
CPC分类号: C07D231/12 , C07D231/42 , C07D233/56 , C07D249/08 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要: Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each directly bonded to a ring carbon and are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) --C(O)H or --C(O)R.sup.5 ; (h) --CO.sub.2 H or --CO.sub.2 R.sup.5 ; (i) --Z.sup.4 --NR.sup.6 R.sup.7 ; (j) --Z.sup.4 --N(R.sup.10)--Z.sup.5 --NR.sup.8 R.sup.9 ; or (k) R.sup.3 and R.sup.4 together may also be alkylene or alkenylene, either of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3, completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; and the remaining symbols are as defined in the specification.
摘要翻译: 式I的化合物抑制内皮素的活性。 符号定义如下:R1,R2,R3和R4各自直接键合到环碳上,并且各自独立地为(a)氢; (b)烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基,芳氧基,芳烷基或芳烷氧基,其中任一个可以被Z1,Z2和Z3取代; (c)卤素; (d)羟基; (e)氰基; (f)硝基; (g)-C(O)H或-C(O)R 5; (h)-CO 2 H或-CO 2 R 5; (i)-Z4-NR6R7; (j)-Z4-N(R10)-Z5-NR8R9; 或(k)R 3和R 4一起也可以是亚烷基或亚烯基,其中任一个可以被Z 1,Z 2和Z 3取代,完成4至8元饱和的,不饱和的或芳族的环与它们 附上 其余符号如说明书中所定义。
-
公开(公告)号:US5612359A
公开(公告)日:1997-03-18
申请号:US487358
申请日:1995-06-07
申请人: Natesan Murugesan
发明人: Natesan Murugesan
IPC分类号: C07D275/02 , A61K31/34 , A61K31/38 , A61K31/40 , A61K31/42 , A61K31/425 , A61P1/00 , A61P1/04 , A61P1/12 , A61P1/16 , A61P3/08 , A61P7/00 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/08 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/04 , A61P25/08 , A61P27/02 , A61P27/14 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D261/02 , C07D261/16 , C07D413/12 , C07D413/14 , C07D417/12 , C07D521/00 , A01K31/465
CPC分类号: C07D231/12 , C07D233/56 , C07D249/08 , C07D261/16 , C07D413/12 , C07D413/14 , C07D417/12
摘要: Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each directly bonded to a ring carbon and are each independently(a) hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ;(c) halo;(d) hydroxyl;(e) cyano;(f) nitro;(g) --C(O)H or --C(O)R.sup.5 ;(h) --CO.sub.2 H or --CO.sub.2 R.sup.5 ;(i) --Z.sup.4 --NR.sup.6 R.sup.7 ;--Z.sup.4 --N(R.sup.10)--Z.sup.5 --NR.sup.8 R.sup.9 ; or(k) R.sup.3 and R.sup.4 together may also be alkylene or alkenylene, either of which may be substituted with Z.sup.1, Z.sup.2 and z.sup.3, completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; and the remaining symbols are as defined in the specification.
摘要翻译: 式
的化合物抑制内皮素的活性。 符号定义如下:R1,R2,R3和R4各自直接键合到环碳上,并且各自独立地为(a)氢; (b)烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基,芳氧基,芳烷基或芳烷氧基,其中任一个可以被Z1,Z2和Z3取代; (c)卤素; (d)羟基; (e)氰基; (f)硝基; (g)-C(O)H或-C(O)R 5; (h)-CO 2 H或-CO 2 R 5; (i)-Z4-NR6R7; -Z4-N(R10)-Z5-NR8R9; 或(k)R 3和R 4一起也可以是亚烷基或亚烯基,其中任一个可以被Z 1,Z 2和Z 3取代,完成4-至8-元饱和的,不饱和的或芳族的环与它们 附上 其余符号如说明书中所定义。 -
公开(公告)号:US07754755B2
公开(公告)日:2010-07-13
申请号:US11231729
申请日:2005-09-21
申请人: Natesan Murugesan , John E. Macor , Zhengxiang Gu , Leena Fadnis
发明人: Natesan Murugesan , John E. Macor , Zhengxiang Gu , Leena Fadnis
IPC分类号: A61K31/405 , A61K31/38 , A61K31/34 , A61K31/28 , C07D209/10 , C07D409/12 , C07D307/91 , C07D307/00
CPC分类号: C07D209/16 , C07D209/14 , C07D405/12 , C07D409/12
摘要: The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
摘要翻译: 本发明提供了根据式I的15-LO抑制剂,含有这些抑制剂的药物组合物和使用这些化合物和组合物治疗与15-LO级联有关的疾病的方法。
-
公开(公告)号:US06673824B1
公开(公告)日:2004-01-06
申请号:US09552543
申请日:2000-04-19
申请人: Natesan Murugesan , John T. Hunt , Philip D. Stein
发明人: Natesan Murugesan , John T. Hunt , Philip D. Stein
IPC分类号: A61K3142
CPC分类号: C07D261/20 , C07D261/16 , C07D261/18
摘要: Compounds of the formula inhibit the activity of endothelin. The symbols are defined as follows: R1, R2 and R3 are each independently (a) hydrogen, except that R1 is other than hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z1, Z2 and Z3; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) —C(O)H or —C(O)R6; (h) —CO2H or —CO2R6; (i) —SH, —S(O)nR6, —S(O)m—OH, —S(O)m—OR6, —O—S(O)m—R6, —O—S(O)mOH or —O—S(O)m—OR6; (j) —Z4—NR7R8; or (k) —Z4—N(R11)—Z5—NR9R10; and the remaining symbols are as defined in the specification.
摘要翻译: 化合物抑制内皮素的活性。 符号定义如下:R 1,R 2和R 3各自独立地为(a)氢,除了R 1不是氢;(b)烷基,烯基,炔基,烷氧基 ,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基,芳氧基,芳烷基或芳烷氧基,其中任何一个可被Z 1,Z 2和Z 3取代;(c)卤素;(d)羟基; e)氰基;(f)硝基;(g)-C(O)H或-C(O)R 6;(h)-CO 2 H或-CO 2 R 6;(ⅰ)-SH,-S O)n R 6,-S(O)m -OH,-S(O)m OR 6,-OS(O)m R 6,-OS(O)mOH或-OS(O) m-OR 6;(j)-Z 4 -NR 7 R 8; 或(k)-Z 4 -N(R 11)-Z 5 -NR 9 R 10;其余符号如说明书中所定义。
-
公开(公告)号:US06638937B2
公开(公告)日:2003-10-28
申请号:US09737201
申请日:2000-12-14
IPC分类号: C07D23332
CPC分类号: C07D401/12 , C07D261/16 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
-
公开(公告)号:US06271248B1
公开(公告)日:2001-08-07
申请号:US09488506
申请日:2000-01-20
申请人: Natesan Murugesan , Joel C. Barrish , John Lloyd
发明人: Natesan Murugesan , Joel C. Barrish , John Lloyd
IPC分类号: A61K3142
CPC分类号: C07D413/12 , C07D261/16
摘要: Compounds of the formula wherein X, Y, R1, R2, R3, R4 and R5 are as described herein, inhibit the activity of endothelin.
摘要翻译: 化合物X,Y,R 1,R 2,R 3,R 4和R 5的化合物如本文所述,抑制内皮素的活性。
-
公开(公告)号:US6080774A
公开(公告)日:2000-06-27
申请号:US728238
申请日:1996-10-08
申请人: Natesan Murugesan , Joel C. Barrish , John Lloyd
发明人: Natesan Murugesan , Joel C. Barrish , John Lloyd
IPC分类号: A61K31/42 , A61P1/00 , A61P3/08 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07D261/16 , C07D413/12 , C07D261/12 , C07D261/14
CPC分类号: C07D413/12 , C07D261/16
摘要: Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: ##STR2## R.sup.2 and R.sup.3 are each independently (a) hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ;(c) halo;(d) hydroxyl;(e) cyano;(f) nitro;(g) --C(O)H or --C(O)R.sup.6 ;(h) --CO.sub.2 H or --CO.sub.2 R.sup.6 ;(i) --SH, --S(O).sub.n R.sup.6, --S(O).sub.m --OH, --S(O).sub.m --OR.sup.6, --O--S(O).sub.m --R.sup.6, --O--S(O).sub.m OH or --O--S(O).sub.m --OR.sup.6 ;(j) --Z.sup.4 --NR.sup.7 R.sup.8 ; or(k) --Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10 ;and the remaining symbols are as defined in the specification.
摘要翻译: 该化合物抑制内皮素的活性。 符号定义如下:R2和R3各自独立地为(a)氢; (b)烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基,芳氧基,芳烷基或芳烷氧基,其中任一个可以被Z1,Z2和Z3取代; (c)卤素; (d)羟基; (e)氰基; (f)硝基; (g)-C(O)H或-C(O)R 6; (h)-CO 2 H或-CO 2 R 6; (ⅰ)-SH,-S(O)nR 6,-S(O)m -OH,-S(O)m -OR 6,-OS(O)m -R 6,-OS(O)mOH或-OS O)m -OR6; (j)-Z4-NR7R8; 或(k)-Z4-N(R11)-Z5-NR9R10; 其余符号如说明书中所定义。
-
公开(公告)号:US5827869A
公开(公告)日:1998-10-27
申请号:US762547
申请日:1996-12-09
申请人: Natesan Murugesan
发明人: Natesan Murugesan
IPC分类号: C07D275/02 , A61K31/34 , A61K31/38 , A61K31/40 , A61K31/42 , A61K31/425 , A61P1/00 , A61P1/04 , A61P1/12 , A61P1/16 , A61P3/08 , A61P7/00 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/08 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/04 , A61P25/08 , A61P27/02 , A61P27/14 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D261/02 , C07D261/16 , C07D413/12 , C07D413/14 , C07D417/12 , C07D521/00
CPC分类号: C07D231/12 , C07D233/56 , C07D249/08 , C07D261/16 , C07D413/12 , C07D413/14 , C07D417/12
摘要: Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each directly bonded to a ring carbon and are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) --C(O)H or --C(o)R.sup.5 ; (h) --CO.sub.2 H or --CO.sub.2 R.sup.5 ; (i) --Z.sup.4 --NR.sup.6 R.sup.7 ; (j) --Z.sup.4 --N(R.sup.10)--Z.sup.5 --NR.sup.8 R.sup.9 ; or (k) R.sup.3 and R.sup.4 together may also be alkylene or alkenylene, either of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3, completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; and the remaining symbols are as defined in the specification.
摘要翻译: 式
的化合物抑制内皮素的活性。 符号定义如下:R1,R2,R3和R4各自直接键合到环碳上,并且各自独立地为(a)氢; (b)烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基,芳氧基,芳烷基或芳烷氧基,其中任一个可以被Z1,Z2和Z3取代; (c)卤素; (d)羟基; (e)氰基; (f)硝基; (g)-C(O)H或-C(o)R 5; (h)-CO 2 H或-CO 2 R 5; (i)-Z4-NR6R7; (j)-Z4-N(R10)-Z5-NR8R9; 或(k)R 3和R 4一起也可以是亚烷基或亚烯基,其中任一个可以被Z 1,Z 2和Z 3取代,完成4至8元饱和的,不饱和的或芳族的环与它们 附上 其余符号如说明书中所定义。 -
公开(公告)号:US5760038A
公开(公告)日:1998-06-02
申请号:US384066
申请日:1995-02-06
IPC分类号: C07D261/14 , A61K31/34 , A61K31/35 , A61K31/422 , A61K31/4418 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/53 , A61P9/12 , C07D237/06 , C07D241/10 , C07D261/02 , C07D309/36 , C07D413/12 , C07D413/14 , A61K31/525 , A61K31/505 , C07D405/00 , C07D409/00
CPC分类号: C07D413/12 , C07D413/14
摘要: Compounds of the formula ##STR1## in which the symbols are as defined herein, inhibit the activity of endothelin.
摘要翻译: 其中符号如本文所定义的式“IMAGE”的化合物抑制内皮素的活性。
-
-
-
-
-
-
-
-
-